Provides Full Year 2013
Guidance
- Fourth quarter and full year 2012 revenue of $18.6
million and $76.2 million, respectively, compared to $18.8 and
$68.1 million for the fourth quarter and full year 2011,
respectively
- Consumable revenue of $9.0 million or 48% of total
revenue for the fourth quarter 2012 compared to $7.2 million or 38%
of total revenue for the fourth quarter 2011
- Installed 120 systems in the fourth quarter 2012, up
13% from the third quarter 2012, bringing total system installed
base to 1,483 systems as of December 31, 2012, up 53% compared to
967 as of December 31, 2011
- Cycles shipped increased 25% to 75,172 for the fourth
quarter 2012, compared to 60,250 for the fourth quarter 2011, and
down 3% sequentially compared to 77,500 cycles shipped for the
third quarter 2012
- $58.6 million cash & cash equivalents, short-term
and long-term investments as of December 31, 2012 compared to $66.9
million as of September 30, 2012
ZELTIQ Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company
focused on developing and commercializing products utilizing its
proprietary controlled-cooling technology platform, today announced
financial results for the fourth quarter and full year ended
December 31, 2012.
Mark Foley, President and Chief Executive Officer, said, "Our
fourth quarter revenue of $18.6 million was up slightly from the
preliminary announcement we made in early January. As part of our
ongoing business and team restructuring, we implemented a number of
changes in the fourth quarter designed to improve our execution and
better position the Company to take advantage of the significant
market opportunity ahead. This included putting in place a new and
experienced management team, restructuring and realigning our sales
infrastructure, and refining our sales and marketing strategy.
Although these significant changes were disruptive to our business
in the near term, we believe they were necessary in order to drive
more consistent growth in both system sales and consumable revenue
over the long term."
Mr. Foley continued, "We have now entered 2013 poised to execute
on our growth strategy. We believe that the changes to our
management team in conjunction with the restructuring of our sales
and marketing organizations will result in improved
performance. Over the course of 2013, we plan to deliver more
predictable system placements, enhanced utilization and accelerated
new product development. We expect the benefits of our
initiatives to ramp up as we progress through the year and
anticipate that these initiatives will translate into more
meaningful revenue growth rates in the second half of the
year. That being said, we continue to have a strong conviction
in both the significant opportunity in the non-surgical fat
reduction market, as well as our unique technology. Finally,
our strong cash position leaves us well capitalized for the
foreseeable future and we continue to focus on improving cash
generation and moving toward positive cash generation."
Fourth Quarter Financial Review
Total net revenue for the fourth quarter 2012 was $18.6 million,
consisting of $9.6 million of system revenue and $9.0 million of
consumable revenue. This compares to total net revenue of $18.8
million, consisting of $11.6 million of system revenue and $7.2
million of consumable revenue for the fourth quarter 2011. Third
quarter 2012 total net revenue was $17.9 million, consisting of
$8.5 million of system revenue and $9.4 million of consumable
revenue. Cycles shipped increased 25% to 75,172 for the fourth
quarter 2012, compared to 60,250 for the fourth quarter 2011, and
down 3% sequentially compared to the 77,500 cycles shipped for the
third quarter 2012.
Gross profit was $12.2 million, or 66% of revenue, for the
fourth quarter 2012, compared to gross profit of $12.3 million, or
66% of revenue, for the fourth quarter 2011. Third quarter 2012
gross profit was $12.0 million, or 67% of revenue.
Operating expenses for the fourth quarter 2012 were $18.7
million, compared to $17.3 million for the fourth quarter 2011 and
$17.1 million for the third quarter 2012.
Net loss attributable to common stockholders for the fourth
quarter 2012 was $6.5 million, compared to $5.8 million for the
fourth quarter 2011 and $5.2 million for the third quarter 2012.
Net loss attributable to common stockholders for the fourth quarter
2012 was $0.18 per share, compared to $0.22 per share for the
fourth quarter 2011, and $0.15 per share for the third quarter
2012. Weighted average diluted shares outstanding for the fourth
quarter 2012, fourth quarter 2011, and third quarter 2012 was 35.8
million, 25.8 million and 35.1 million, respectively.
Full Year Financial Review
Total net revenue for the full year 2012 was $76.2 million,
consisting of $39.1 million of system revenue and $37.1 million of
consumable revenue. This compares to total net revenue of $68.1
million, consisting of $46.5 million of system revenue and $21.6
million of consumable revenue for the full year 2011. Cycles
shipped increased 58% to 300,692 for the full year 2012, compared
to 190,314 for the full year 2011.
Gross profit was $50.7 million, or 67% of revenue, for the full
year 2012, compared to gross profit of $42.0 million, or 62% of
revenue, for the full year 2011.
Operating expenses for the full year 2012 were $80.7 million,
compared to $50.7 million for the full year 2011.
Net loss attributable to common stockholders for the full year
2012 was $30.1 million, compared to $14.7 million for the full year
2011. Net loss attributable to common stockholders for the full
year 2012 was $0.87 per share, compared to a net loss of $1.96 per
share for the full year 2011. Weighted average diluted shares
outstanding for the full year 2012 and full year 2011 were 34.8
million and 7.5 million, respectively.
Full Year 2013 Financial Guidance
- Revenue growth of approximately 10%
- Consumable revenue between 45% to 50% of total revenue
- Gross margin of approximately 66%
- Operating expenses between 97% to 100% of total revenue
- Weighted average basic shares of common stock outstanding of
approximately 36 million
Conference Call
ZELTIQ will hold a conference call on Tuesday, March 12, 2013,
at 5:00 p.m. ET to discuss the results. The dial-in numbers are
(877) 280-7291 for domestic callers and (707) 287-9361 for
international callers. A live webcast of the conference call will
be available online from the investor relations page of the
Company's corporate website at www.coolsculpting.com.
After the live webcast, the call will remain available on
ZELTIQ's website, www.coolsculpting.com, until ZELTIQ releases its
first quarter 2013 financial results. In addition, a telephonic
replay of the call will be available until the Company releases its
first quarter 2013 financial results. The replay dial-in numbers
are (855) 859-2056 for domestic callers and (404) 537-3406 for
international callers. Please use the replay pin number
99079360.
About ZELTIQ® Aesthetics
ZELTIQ Aesthetics is a medical technology company focused on
developing and commercializing products utilizing its proprietary
controlled-cooling technology platform. The Company's first
commercial product, the CoolSculpting System, is designed to
selectively reduce stubborn fat bulges that may not respond to diet
or exercise. CoolSculpting is based on the scientific principle
that fat cells are more sensitive to cold than the overlying skin
and surrounding tissues. CoolSculpting utilizes patented technology
of precisely controlled cooling to reduce the temperature of fat
cells in the treated area, which is intended to cause fat cell
elimination through a natural biological process known as
apoptosis, without causing scar tissue or damage to the skin,
nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to
safely, noticeably, and measurably reduce the fat layer within a
treated fat bulge without requiring the patient to diet or
exercise.
Forward-Looking Statements
The statements made in this press release regarding ZELTIQ's
belief regarding the benefits it expects from its new management
and sales and marketing teams and initiatives, and the information
under the caption "Full Year 2013 Financial Guidance," are
forward-looking statements. The words "believe," "should," "will,"
"expect," and "guidance" and similar words that denote future
events or results identify these forward-looking
statements. You should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond ZELTIQ's control and that could materially affect the
company's actual business operations and financial performance and
condition. Factors that could materially affect ZELTIQ's business
operations and financial performance and condition include, but are
not limited to: the recent additions to the commercial sales team
may require more time than ZELTIQ expects to integrate these
employees into the company; less than anticipated growth in the
number of physicians electing to purchase CoolSculpting Systems;
patient demand for CoolSculpting procedures may be lower than
ZELTIQ expects; product or procedure announcements by competitors
may decrease demand for CoolSculpting procedures; ZELTIQ
may incorrectly estimate or control its future expenditures;
ZELTIQ's sales and marketing plans may fail to increase sales as
ZELTIQ expects; as well as those other risks and uncertainties set
forth in ZELTIQ's Current Report on Form 10-Q for the fiscal
quarter ended September 30, 2012, filed with the SEC on November 8,
2012. These forward-looking statements speak only as of the date of
this press release. ZELTIQ expressly disclaims any obligation to
update information contained in these forward-looking statements
whether as a result of new information, future events or
otherwise.
|
|
ZELTIQ Aesthetics,
Inc. |
Unaudited, Condensed
Consolidated Statements of Operations |
(In thousands, except
share and per share data) |
|
|
|
|
|
|
Three Months
Ended |
Year
Ended |
|
December
31, |
December
31, |
|
2012 |
2011 |
2012 |
2011 |
Revenues |
$ 18,597 |
$ 18,798 |
$ 76,194 |
$ 68,144 |
Cost of revenues |
6,411 |
6,469 |
25,506 |
26,101 |
Gross profit |
12,186 |
12,329 |
50,688 |
42,043 |
Operating expenses: |
|
|
|
|
Research and development |
3,477 |
2,948 |
12,693 |
10,488 |
Sales and marketing |
11,536 |
10,281 |
51,167 |
28,953 |
General and administrative |
3,697 |
4,059 |
16,867 |
11,299 |
Total operating expenses |
18,710 |
17,288 |
80,727 |
50,740 |
Loss from operations |
(6,524) |
(4,959) |
(30,039) |
(8,697) |
Interest income (expense), net |
25 |
(9) |
129 |
(93) |
Other income (expense), net |
21 |
(353) |
(92) |
(765) |
Loss before provision for income taxes |
(6,478) |
(5,321) |
(30,002) |
(9,555) |
Provision for income taxes |
37 |
48 |
141 |
48 |
Net loss |
(6,515) |
(5,369) |
(30,143) |
(9,603) |
Cumulative dividends on convertible preferred
stock |
— |
(408) |
— |
(5,099) |
Net loss attributable to common
stockholders |
$ (6,515) |
$ (5,777) |
$ (30,143) |
$ (14,702) |
Net loss per share attributable to common
stockholders, basic and diluted |
$ (0.18) |
$ (0.22) |
$ (0.87) |
$ (1.96) |
Weighted average shares of common stock
outstanding used in computing net loss attributable to common
stockholders, basic and diluted |
35,764,666 |
25,846,891 |
34,776,380 |
7,506,282 |
|
|
ZELTIQ Aesthetics,
Inc. |
Unaudited Condensed
Consolidated Balance Sheets |
(In
thousands) |
|
|
|
|
December 31,
2012 |
December 31,
2011 |
ASSETS |
|
|
CURRENT ASSETS: |
|
|
Cash and cash equivalents |
$ 22,876 |
$ 83,908 |
Short-term investments |
22,563 |
— |
Accounts receivable, net |
7,133 |
4,941 |
Inventory, net |
10,871 |
4,476 |
Prepaid expenses and other
current assets |
3,600 |
2,385 |
Total current assets |
67,043 |
95,710 |
Long-term investments |
13,141 |
— |
Restricted cash |
469 |
255 |
Property and equipment, net |
2,336 |
2,144 |
Intangible asset, net |
7,181 |
7,882 |
Other assets |
99 |
8 |
Total assets |
$ 90,269 |
$ 105,999 |
LIABILITIES AND STOCKHOLDERS'
EQUITY |
|
|
CURRENT LIABILITIES: |
|
|
Accounts payable |
$ 4,976 |
$ 4,061 |
Accrued liabilities |
11,076 |
6,878 |
Deferred revenue, net of
deferred costs |
1,401 |
375 |
Current portion of notes
payable |
— |
310 |
Total current liabilities |
17,453 |
11,624 |
Other non-current liabilities |
236 |
72 |
Total liabilities |
$ 17,689 |
$ 11,696 |
Total stockholders' equity |
72,580 |
94,303 |
Total liabilities and
stockholders' equity |
$ 90,269 |
$ 105,999 |
CONTACT: Investor Relations:
Patrick F. Williams
ZELTIQ, Senior Vice President and CFO
925-474-2500
Nick Laudico / Amy Glynn
The Ruth Group
646-536-7030 / 7023
nlaudico@theruthgroup.com
aglynn@theruthgroup.com
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jul 2023 to Jul 2024